
Opinion|Videos|August 8, 2024
Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC
The panel discusses treatment considerations for consolidation durvalumab.
Advertisement
Episodes in this series

How do you select patients for consolidation durvalumab?
Advertisement
Related to this article

Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.

Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.

Frailty is common among older adults with blood cancers and strongly predicts survival, independent of age.

The PCR-based OncoMate MSI Dx Analysis System can now identify patients with MSI-H solid tumors who may be eligible for pembrolizumab.

The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.

Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pimicotinib for Symptomatic TGCT
2
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
3
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5

